Merck and Eisai Provide Update on Phase III Trials of KEYTRUDA^® (Pembrolizumab) plus LENVIMA^® (Lenvatinib) in Certain Patients with Advanced Melanoma (LEAP-003) and Metastatic Colorectal Cancer (LEAP-017)

Merck and Eisai provided updates on two Phase III trials, LEAP-003 and LEAP-017 investigating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai.